Opioid abuse is a growing medical challenge, yet few developments have been made in its treatment in recent years. The market requires clarification of the goals of therapy - to remove the addictive behavior or to just manage the addiction and modify the impact on the abuser’s life?
Scope
Reviews the overall opioid abuse market
Identifies the current treatments available to treat opioid addiction
Highlights the various drugs in clinical development for opioid addiction
Outlines the key unmet needs in treatment
Highlights
Treatment rates need to be increased as only 20% of prescription and non-prescription abuse patients are being treated for their addiction. Successful treatment that enables a patient to live drug free is rare and this may be impacting the willingness of patients and their family to seek treatment, in addition to deferring physicians from using it.
A lack of novel approaches may mean the market will remain flat in terms of sales volume. Despite potential treatments such as Wex’s non-narcotic Tetrodin in clinical development, the pipeline is weak as no therapies are expected to enter the market in the immediate future, and the vast majority of pipeline drugs contain some level of opioid.
Reasons to Purchase
Assess the strengths and weaknesses of current opioid replacement therapies available on the market
Evaluate the unmet needs in the opioid addicted population
Identify potential licensing opportunities within the drug abuse pipeline
